Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-BCMA in Relapsed/Refractory Multiple Myeloma
NCT05346198Phase 1Active, not recruiting
- Sponsor
- Simnova Biotherapeutics
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-BCMA in multiple myeloma (MM), sponsored by Simnova Biotherapeutics. Primary endpoints: Incidence of all adverse events and serious adverse events and BCMA-CART Maximum Tolerable Dose (MTD) and/or Recommended Dose (RD). Started Mar 2021; status: active, not recruiting.
02
Drugs
CART-BCMA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05346198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346198.